Trump Administration Considers Antitrust Probe into Homebuilders
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 06 2026
0mins
Should l Buy DHI?
Source: stocktwits
- Antitrust Investigation Potential: The Trump administration is considering an antitrust investigation into U.S. homebuilders, although no final decision has been made, raising concerns about the industry's outlook and potentially impacting investor confidence.
- Stock Price Fluctuations: Following this news, shares of Lennar Corp. (LEN) and D.R. Horton (DHI) fell approximately 2%, reflecting the market's sensitivity to potential regulatory risks, which could lead to short-term capital outflows.
- Industry Impact: Should the investigation proceed, it could have far-reaching implications for the entire homebuilding sector, especially in the current market environment where companies may face stricter compliance requirements, thereby affecting profitability.
- Future Developments Monitoring: As the investigation could commence in the coming weeks, investors need to closely monitor related developments to assess the long-term impacts on the market and individual stocks, particularly in the context of the recovering real estate market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DHI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DHI
Wall Street analysts forecast DHI stock price to fall
13 Analyst Rating
4 Buy
7 Hold
2 Sell
Hold
Current: 164.220
Low
117.00
Averages
160.58
High
195.00
Current: 164.220
Low
117.00
Averages
160.58
High
195.00
About DHI
D.R. Horton, Inc. is a homebuilding company. The Company is primarily engaged in the acquisition and development of land and the construction and sale of residential homes, with operations in over 126 markets across 36 states. The Company’s segments include Homebuilding, Rental, Forestar, Financial Services, and Other. The Homebuilding division is primarily engaged in the acquisition and development of land and the construction and sale of residential homes. The Company’s rental segment consists of single-family and multifamily rental operations. The single-family rental operations construct and lease single-family homes within a community and then generally market each community for a bulk sale of rental homes. The Forestar segment is a residential lot development company with operations in 64 markets across 23 states. The Financial services segment provides mortgage financing and title agency services to homebuyers in many of the Company’s homebuilding markets.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Barclays Raises Price Target: Barclays has increased its price target for a specific stock from $128 to $140.
- Market Implications: This adjustment reflects Barclays' positive outlook on the stock's performance and potential growth in the market.
See More
- Strong Retail Sales: US March retail sales rose 1.7% month-over-month, exceeding expectations of 1.4% and marking the largest increase in a year, indicating robust consumer spending that could bolster economic recovery and market confidence.
- Earnings Support: UnitedHealth Group (UNH) reported Q1 adjusted EPS of $9.23, significantly above the consensus of $6.57, raising its full-year forecast to above $18.25, which has driven health insurance stocks higher and reflects industry resilience.
- Fed Nomination in Focus: Kevin Warsh's confirmation hearing before the Senate Banking Committee is drawing attention; despite facing an investigation hurdle, Warsh's commitment to an independent Fed and prioritizing inflation control could influence future monetary policy directions.
- International Tensions Impact Oil Prices: WTI crude oil prices fell over 1% as Iran is set to attend peace talks with the US, while the closure of the Strait of Hormuz threatens to exacerbate the global energy crisis, affecting market sentiment.
See More
- Market Performance: The S&P 500 Index fell by 0.13%, and the Dow Jones Industrial Average also declined by 0.13%, while the Nasdaq 100 saw a slight increase of 0.02%, reflecting market volatility influenced by oil price rebounds and economic data.
- Strong Economic Data: March retail sales rose by 1.7% month-over-month, exceeding expectations of 1.4%, marking the largest increase in a year, indicating robust consumer spending that may support stock prices.
- Oil Price Recovery: WTI crude oil prices rebounded by over 2% as market speculation intensified regarding Iran's participation in upcoming peace talks, potentially exacerbating the global energy crisis.
- Impressive Earnings Reports: UnitedHealth Group reported Q1 adjusted EPS of $9.23, significantly above the consensus of $6.57, leading to a stock price increase of over 7% and raising its full-year earnings forecast, showcasing strong performance in the health insurance sector.
See More
- Market Decline: The S&P 500 index fell by 0.63%, the Dow Jones Industrial Average dropped by 0.59%, and the Nasdaq 100 index decreased by 0.42%, reflecting investor concerns over the uncertainty surrounding Iran's geopolitical situation, which dampened market sentiment.
- Oil Price Rebound Impact: WTI crude oil prices rebounded by over 2% after Iran announced it would not attend peace talks, raising fears of a deepening global energy crisis, which could further hinder economic recovery.
- Supportive Economic Data: March retail sales rose by 1.7% month-over-month, surpassing expectations of 1.4%, indicating robust consumer spending that may provide some support for the stock market, despite overall market pressures.
- Fed Nominee Supports Independence: Fed Chair nominee Kevin Warsh emphasized the importance of monetary policy independence and controlling inflation in his Senate Banking Committee statement, which could positively influence market confidence.
See More
- Revenue and Profit Performance: D.R. Horton reported a consolidated pretax income of $867 million and revenues of $7.6 billion for Q2 FY2026, achieving a pretax profit margin of 11.5%, demonstrating resilience amid market pressures.
- Sales Order Growth: Net sales orders increased by 11% year-over-year to 24,992 homes, with total order value rising 10% to $9.2 billion, aligning with the company's business plan and indicating a gradual recovery in market demand.
- Future Outlook Adjustment: The company expects Q3 revenues to range between $8.8 billion and $9.3 billion, with full-year revenue guidance adjusted to approximately $33.5 billion to $34.5 billion, reflecting cautious optimism regarding market conditions.
- Shareholder Return Plan: In Q2, D.R. Horton repurchased 6 million shares for $904 million, reducing outstanding shares by 8%, while also planning approximately $2.5 billion in stock buybacks and $500 million in dividend payments, underscoring the company's commitment to shareholder returns.
See More
- Valmont Industries Strong Performance: The agricultural products and infrastructure company saw its stock rise 12% after reporting better-than-expected first-quarter results, driven by strong demand in its North American utility business, while also raising the lower end of its full-year earnings guidance, indicating market confidence in future growth.
- Pitney Bowes Revenue Beat: Mailing equipment and services giant Pitney Bowes reported first-quarter revenue of $477 million, exceeding the market consensus of $465.9 million, leading to an 8% stock increase, which reflects the company's solid performance in a competitive market.
- UnitedHealth Earnings Surprise: UnitedHealth reported first-quarter earnings of $7.23 per share and revenue of $11.72 billion, both surpassing analyst expectations, resulting in a 9% stock increase, while the company also raised its full-year earnings outlook, showcasing its strong market position.
- Quest Diagnostics Strong Results: Laboratory testing services company Quest Diagnostics posted first-quarter earnings of $2.50 per share, exceeding the expected $2.37, with revenue reaching $2.90 billion, surpassing the $2.83 billion consensus estimate, leading to a 5.2% stock increase, highlighting its competitive edge in the industry.
See More











